Core Viewpoint - The article discusses the development and potential of the Fanzor system, a compact RNA-guided DNA nuclease, for precise genome editing in eukaryotic cells, highlighting its advantages over traditional Cas9 systems and its application in disease treatment [3][9]. Group 1: Fanzor System Overview - Fanzor is a newly discovered CRISPR-like system that allows for precise genome editing in eukaryotic organisms, with a compact size of 400-700 amino acids, making it suitable for delivery via a single AAV vector [3][9]. - The traditional AAV delivery system has a maximum packaging capacity of 4.7 kb, which is insufficient for larger Cas proteins like SpCas9 and AsCas12a, necessitating the use of dual AAV vectors [3]. Group 2: Research Developments - A study published by a team from Fudan University introduced an engineered hypercompact Fanzor-ωRNA system, which demonstrated enhanced genome editing activity, achieving efficiency improvements of 6-129 times compared to previous versions [4][11]. - The engineered SpuFz1 V4 system, derived from soil fungus, showed strong genome editing capabilities in human cells, marking it as the most active member of the Fanzor family [9][11]. Group 3: Applications and Potential - The compact structure of SpuFz1 V4 allows for effective in vivo delivery using a single AAV, enabling robust genome editing in animal models, such as efficient editing of the Nfkb1 gene in mouse retinas [10][11]. - The research indicates that the Fanzor platform can be developed into base editors, facilitating efficient single-base editing, which has significant implications for genetic research and therapeutic applications [5][9].

Core Viewpoint - The company BaiO Saite (688796.SH) is set to launch an IPO on the Sci-Tech Innovation Board, focusing on gene editing and related services, following its previous listing on the Hong Kong Stock Exchange in 2022 as the "first gene editing stock" [3]. Group 1: Company Overview - BaiO Saite operates four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [3]. - The company has developed a stable and efficient gene editing platform, completing approximately 5,300 customized gene editing projects and creating over 4,300 gene-edited animal and cell line models by June 30, 2025 [7]. Group 2: Financial Information - The IPO price is set at 26.68 yuan per share, with an institutional offering price of 27.88 yuan, resulting in a market capitalization of 10.66 billion yuan [4]. - The company’s earnings per share (EPS) is projected at a price-to-earnings (P/E) ratio of 519.12, significantly higher than the industry average P/E of 39.31 [4]. Group 3: Fundraising and Investment Plans - The company plans to allocate raised funds as follows: 4.54 billion yuan (38.28%) for early drug development services, 3.16 billion yuan (26.70%) for antibody drug research and evaluation, 1.65 billion yuan (13.92%) for preclinical research, and 2.50 billion yuan (21.10%) for working capital [7]. Group 4: Business Performance - The company has shifted to a direct sales model, with the mode animal sales segment accounting for 44.2% of total revenue in the first half of the year, generating 274 million yuan [9]. - Gilead Sciences, Inc. is the largest client, contributing 88 million yuan, or 14.25% of total revenue in the same period [9]. Group 5: Workforce Changes - The number of R&D personnel decreased from 627 at the end of 2022 to 403 by mid-2025, a reduction of over 30%, attributed to the completion of a large-scale R&D phase [8].

Core Viewpoint - The company, BaiAo SaiTu, is launching an IPO on the Sci-Tech Innovation Board, focusing on gene editing and related services, despite a significant reduction in R&D personnel. Group 1: Company Overview - BaiAo SaiTu is recognized as the "first stock in gene editing" and was listed on the Hong Kong Stock Exchange in 2022 [2] - The company operates four technical platforms: gene-edited model animals, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [2] - As of June 30, 2025, BaiAo SaiTu has completed approximately 5,300 customized gene editing projects and developed over 4,300 gene-edited animal and cell line models [2] Group 2: R&D and Personnel Changes - The number of R&D personnel at BaiAo SaiTu decreased from 627 at the end of 2022 to 403 by mid-2025, a reduction of over 30% [3] - The company stated that the large-scale R&D phase concluded in Q3 2023, leading to a significant drop in internal R&D projects and subsequent personnel optimization [3] Group 3: Business Performance - BaiAo SaiTu's business segments include preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and gene editing services [3] - Model animal sales have become increasingly significant, generating revenue of 274 million yuan in the first half of the year, accounting for 44.2% of total revenue [3] - The largest client, Gilead Sciences, Inc., contributed 88 million yuan in revenue during the first half of the year, representing 14.25% of total revenue [3]

Core Viewpoint - The company, Bai'ao Saitu, is set to launch an IPO on the Sci-Tech Innovation Board, focusing on gene editing and related services, after previously being listed in Hong Kong as the "first gene editing stock" [1]. Group 1: Company Overview - Bai'ao Saitu operates four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1]. - The company has completed approximately 5,300 customized gene editing projects and developed over 4,300 types of gene-edited animals and cell line models by June 30, 2025 [6]. Group 2: Financial Aspects - The company plans to raise funds for various projects, including 4.54 billion for early drug development services (38.28%), 3.16 billion for antibody drug research and evaluation (26.70%), 1.65 billion for preclinical research (13.92%), and 2.50 billion for working capital (21.10%) [5]. - In the first half of this year, the revenue from model animal sales reached 274 million, accounting for 44.2% of total revenue [7]. Group 3: Human Resources - The number of R&D personnel decreased from 627 at the end of 2022 to 403 by June 30, 2025, a reduction of over 30% due to the completion of a large-scale R&D phase [6]. Group 4: Client Base - The primary clients of Bai'ao Saitu include pharmaceutical R&D, biotechnology companies, and research institutions, with Gilead Sciences, Inc. being the largest client, contributing 88 million in revenue, which is 14.25% of total revenue for the period [7].

Group 1: Impact of National Drug Procurement - The company has been significantly affected by the 8th and 9th batches of national drug procurement, with major products entering procurement and experiencing price reductions of up to 70% [2][3] - Temozolomide capsules saw a price drop of 62% during the 4th batch procurement, yet sales revenue increased by 109% despite the price cut [5][6] - The average price of several biological products decreased by approximately 15% due to regional alliance procurement [3] Group 2: Business Model and Product Structure - The company operates as a biopharmaceutical enterprise, covering drug research, production, and marketing, with a focus on expanding into the health sector [4] - The product structure has shifted from a high reliance on major products to a more diversified portfolio, enhancing risk resistance [6][11] - Oral solid preparations now account for over 50% of the product mix, reflecting a significant change from previous years when injectables dominated [12] Group 3: New Product Launches and Profit Contribution - The contribution of new and upcoming products to profits depends on their procurement success and market expansion of non-procurement products [6] - The company has a rich pipeline of new products, indicating a potential shift towards a multi-product profit model [6] Group 4: Production Capacity and Operations - The company has eight major production bases, with some operating at full capacity and others reserved for future product launches [7] - Plans are in place to transfer some production to lower-cost locations to participate in larger-scale procurement [7] Group 5: Sales Performance and Key Products - The top ten products by sales revenue in the first three quarters of 2025 include: - Fuzhifu: 59.6 million CNY - Temozolomide capsules: 55.2 million CNY - Oseltamivir phosphate capsules: 52.7 million CNY [8] - Changes in invoicing models have affected reported sales revenue, complicating the assessment of actual sales performance [8] Group 6: International Investments and Collaborations - The company holds a 30% stake in Diapin Therapeutics, focusing on innovative drug development for diabetes and cardiovascular diseases [9] - ATGC Company is developing a unique therapeutic antibody platform using genetically modified rabbits, with significant progress reported [10] Group 7: Market Position and Stock Performance - The company has faced a prolonged adjustment period due to policy changes and competitive pressures, with market capitalization remaining below 10 billion CNY for years [13] - Management emphasizes the importance of developing competitive products to improve performance and shareholder returns [13] Group 8: Recent Investments - The company invested 10 million CNY in Changfeng Pharmaceutical, which is now publicly listed, holding a 3.68% stake valued at nearly 500 million CNY [15] - The investment in Xuan Bamboo Biotechnology also resulted in a public listing, with a 0.34% stake valued at approximately 206 million CNY [15]

Core Viewpoint - The research teams from Heilongjiang Academy of Agricultural Sciences and Sun Yat-sen University have successfully developed the world's first single-gene and multi-gene edited Min pigs, marking a significant advancement in genetic editing for livestock breeding [1] Group 1: Single-Gene Editing Achievements - The teams achieved single-gene editing of the IGF2 gene, resulting in Min pigs with improved meat quality [1] - They also edited the BMP15 gene, leading to Min pigs with enhanced reproductive capabilities [1] Group 2: Multi-Gene Editing Achievements - The teams combined the BMP15, MSTN, and CD163 genes to create three-gene edited Min pigs that exhibit increased production, high reproductive capacity, and disease resistance [1] - Another combination of the TYR, SGK3, and GHRHR genes resulted in three-gene edited Min pigs characterized by hairlessness, albinism, and dwarfism [1] Group 3: Broader Implications and Future Research - The research also included the Five-Finger Mountain pig, resulting in growth-related PROP1 gene edited pigs and high reproductive capacity FecB gene edited pigs [1] - The findings provide new pathways for high-quality Min pig production and open new avenues for the breeding of medical model pigs and pet pigs, indicating significant theoretical and practical implications [1] - The teams plan to enhance trait evaluation of gene-edited pigs and continue research on other gene-edited pigs, contributing to the protection of local pig resources and the development of the life and health industry in China [1]

Investment Rating - The investment rating for the company is positioned in the mid-to-lower range, with an AHP score of 2.38, placing it in the 38.9% percentile of the overall score [2][5]. Core Insights - The company, Baiaosaitu, is a leading preclinical CRO and biotechnology firm, focusing on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development. The gene editing technology is a significant foundation for its business, having developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [2][12]. - The company has expanded its business into innovative model animal sales, having developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice. The establishment of a production center compliant with AAALAC international standards supports large-scale breeding and supply of model animals [12][30]. - The company has established a comprehensive pharmacology and efficacy evaluation system, serving approximately 950 partners globally and completing over 6,350 drug evaluation projects. It has collaborations with 9 of the top 10 global pharmaceutical companies in the pharmacology and efficacy sector [2][18]. Summary by Sections AHP Score and Expected Allocation Ratio - The AHP score for Baiaosaitu is 2.38, indicating a mid-to-lower performance level in the AHP model [5][6]. Company Fundamentals and Highlights - Baiaosaitu has built platforms for gene editing, model animal breeding, preclinical pharmacology evaluation, and antibody drug development, evolving from a single-service biotechnology company to a leading biopharmaceutical enterprise [6][12]. - The company’s revenue composition shows that model animal sales accounted for approximately 44% of total revenue in the first half of 2025, followed by antibody development and preclinical pharmacology services [7][8]. Financial Comparison with Peers - From 2022 to the first half of 2025, Baiaosaitu's revenue was lower than that of comparable companies, with revenues of 5.34, 7.17, 9.80, and 6.21 billion yuan respectively. However, the net profit turned positive in 2024, with a net profit margin that improved over time [22][24]. - The company’s gross margin was relatively high, with figures of 73.38%, 70.59%, 77.67%, and 74.39% from 2022 to the first half of 2025, outperforming the average of comparable companies [24][25]. Fundraising Projects and Development Vision - The company plans to raise funds for projects including the construction of a drug early research service platform, antibody drug research and evaluation projects, and preclinical research projects, which are expected to enhance its core competitiveness and solidify its industry position [30][31].

Investment Rating - The report assigns a rating of "Subscribe" for the company, with an AHP score of 2.38, placing it in the 38.9% percentile of the AHP model [7][8]. Core Insights - The company, BaiAoSaiTu, is positioned as a leading preclinical CRO and biotechnology firm, with a focus on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development [8][9]. - The company has developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [13][14]. - BaiAoSaiTu has established a comprehensive preclinical pharmacology and efficacy evaluation system, collaborating with nine of the top ten global pharmaceutical companies [18][20]. - The company has turned profitable in 2024, with improving profitability metrics and a richer variety of mouse strains compared to peers [26][28]. Summary by Sections 1. AHP Score and Expected Allocation Ratio - BaiAoSaiTu's AHP score is 2.38, indicating a mid-to-low level performance in the AHP model [7][8]. 2. Fundamental Highlights and Features 2.1 Gene Editing Technology and Innovative Model Animal Development - BaiAoSaiTu has built platforms for gene editing and model animal breeding, evolving from a single service provider to a leading biopharmaceutical enterprise [8][9]. - The company has developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice [14][15]. 2.2 Antibody and Drug Collaboration Development - The company has created the RenMice platform, known for its high humanization level, facilitating the discovery and development of diverse antibody molecules [16][17]. - BaiAoSaiTu's "Thousand Mice, Ten Thousand Antibodies" initiative aims to discover antibodies against over 1,000 potential drug targets, enhancing its antibody library [17][18]. 2.3 Expansion of Preclinical Pharmacology and Efficacy Evaluation Services - BaiAoSaiTu has established a robust pharmacology and efficacy evaluation system, serving over 950 partners and completing more than 6,350 drug evaluation projects [20][21]. 3. Comparable Company Financial Metrics 3.1 Diverse Product Involvement and Rich Mouse Strain Resources - BaiAoSaiTu's humanized mouse strains exceed 1,700, compared to its peers, providing a competitive edge in preclinical evaluations [25][24]. 3.2 Revenue and Profitability Comparison - The company's revenue from 2022 to 2025 H1 was lower than peers, but it achieved profitability in 2024, with a compound annual growth rate of 35.52% [26][27]. 3.3 Higher Gross Margin and Net Profitability - BaiAoSaiTu's gross margin from 2022 to 2025 H1 averaged above 70%, with a net profit margin improving to 7.73% in 2025 H1, outperforming comparable drug development companies [28][29]. 3.4 R&D Expense Ratio Comparison - The company's R&D expense ratio was above the industry average in 2022 and 2023, reflecting its commitment to extensive research and development [31][32]. 4. Fundraising Projects and Development Vision - The company plans to raise funds for early drug development service platform construction, antibody drug research and evaluation, and preclinical research projects, enhancing its core competitiveness [34][35].

Group 1: Company Overview - Moer Thread is a leading company in the domestic GPU field, recognized as one of the few enterprises with full-function GPU R&D capabilities, and will become the "first domestic GPU stock" upon listing [1] - The company has successfully launched four generations of GPU architecture, covering various application areas including AI computing, high-performance computing, and graphics rendering [2] - Bai Ao Sai Tu is a global leader in innovative technology-driven biotechnology, focusing on preclinical CRO and drug development services based on self-developed gene editing technology [3] Group 2: Financial Performance - Moer Thread's projected revenues for 2022, 2023, and 2024 are 0.46 billion, 1.24 billion, and 4.38 billion respectively, with net losses of -1.894 billion, -1.703 billion, and -1.618 billion [2] - Bai Ao Sai Tu's projected revenues for the same period are 5.34 billion, 7.17 billion, and 9.8 billion, with net losses of -0.602 billion, -0.383 billion, and a profit of 0.034 billion in 2024 [4] Group 3: Fundraising and Investment Plans - Moer Thread plans to use the funds raised for the development of next-generation AI training and inference chips, graphics chips, and AISoC chips, as well as to supplement working capital [2] - Bai Ao Sai Tu intends to invest the raised funds in early drug development service platform construction, antibody drug R&D and evaluation projects, and preclinical R&D projects [4]

New IPOs This Week - This week, two new stocks are scheduled for subscription: Moer Thread (688795) and Baiaosaitu (688796) [1][3] - Moer Thread focuses on the research, design, and sales of GPUs and related products, being one of the few companies in China with full GPU development capabilities [1][4] - The subscription price for Moer Thread is set at 114.28 CNY per share, making it the most expensive new stock this year [1][4] - Baiaosaitu, established in 2009, is a preclinical CRO and biopharmaceutical company specializing in gene editing technology [6][7] Company Profiles - Moer Thread was founded in 2020 and has developed a proprietary MUSA architecture to create differentiated competitive advantages in the GPU market [5] - The company has launched four generations of GPU architectures and aims to provide computing acceleration platforms for AI, digital transformation, and scientific computing [4][5] - Baiaosaitu has completed approximately 5,300 gene editing projects and developed over 4,300 gene-edited models, focusing on various diseases [7] Market Position and Comparisons - Moer Thread's revenue scale is below the average of comparable companies, which have an average revenue of 2.887 billion CNY for 2024, while its gross profit margin is in the mid-to-high range compared to peers [5] - Baiaosaitu's revenue scale is also below the average of its comparable companies, which have an average revenue of 1.35 billion CNY for 2024, with a gross profit margin of 59.07% [7] Upcoming Listings - Hai'an Group (001233) is set to be listed this week, recognized as one of the few companies globally capable of mass-producing all-steel giant tires [8]